Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000822
Status:
COMPLETED
Last Update Posted:
2021-10-29
First Post:
1999-11-02
Brief Title:
A Phase III Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500mm3 CD4 T Cells and 200-400mm3 CD4 T Cells
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Conditions & Keywords Data
Conditions:
| Name |
|---|
| HIV Infections |
Keywords:
| Name | View |
|---|---|
| HIV Therapeutic Vaccine | View |
| Vaccines Synthetic | View |
| Didanosine | View |
| Drug Therapy Combination | View |
| HIV Envelope Protein gp160 | View |
| Acquired Immunodeficiency Syndrome | View |
| AIDS-Related Complex | View |
| Stavudine | View |
| HIV Protease Inhibitors | View |
| AIDS Vaccines | View |
| Ritonavir | View |
| Reverse Transcriptase Inhibitors | View |